Annual Report

Overview

The report presents Medivir's 2025 focus on two lead drug programs, fostrox and MIV-711, alongside partnerships and a sustainability section. It identifies sustainability as core to the company and links its work particularly to SDGs 3, 8, 9 and 12. The Group reported net sales of SEK 8,506 thousand for 2025.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services